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Abstract
A sustained release system for interleukin-2 (IL-2), and IL-2 mini-pellet (IL-2 mp), was de-
veloped by fusing IL-2 into a needle shaped collagen. Serum concentration of IL-2 after a single
subcutaneous injection of the IL-2 mp into C57BL/6 mice remained elevated longer than after
an injection of aqueous IL-2. IL-2 in the serum became undetectable by 6h after a subcutaneous
injection of 1 x 10(6) unit of IL-2 in phosphate-buffered saline (PBS). In contrast, after a single
subcutaneous injection of IL-2 mp containing the same amount of IL-2, the concentration of IL-2
increased to its maximum at 6h after injection, then began to decrease gradually. IL-2 was de-
tected even on the third day after a single subcutaneous injection of one IL-2 mp. Augmentation
of NK activity and generation of IL-2 activated killer cells were observed in the spleen from day
1–day 3 after a single subcutaneous injection of IL-2 mp into C57BL/6 mice. This activation
was not observed following a single subcutaneous injection of the same amount of IL-2 in PBS.
Adoptive immunotherapy by a single subcutaneous injection of IL-2 mp followed by intravenous
injections of in vitro cultured IL-2 activated killer cells showed better results in decreasing the
number of metastases of Lewis lung carcinoma in C57BL/6 mice than immunotherapy using IL-2
solution.(ABSTRACT TRUNCATED AT 250 WORDS)
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